Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Lisbon, Portugal – 17 March 2019: A drug commonly used to treat high blood pressure and angina (chest pain) is associated with an increased risk of out-of-hospital sudden cardiac arrest, according to results from the European Sudden Cardiac Arrest network (ESCAPE-NET) presented today at EHRA 2019.1
Sudden cardiac arrest causes around half of cardiac deaths in Europe and one in five natural deaths. The heart stops pumping after a cardiac arrhythmia (ventricular fibrillation/tachycardia); this is lethal in minutes if untreated. ESCAPE-NET was set up to find the causes of these arrhythmias, so they can be prevented.
Dr Hanno Tan, ESCAPE-NET project leader and cardiologist, Academic Medical Centre, Amsterdam, the Netherlands, urged caution when interpreting these results. He said: “The findings need to be replicated in other studies before action should be taken by doctors or patients.”
The study examined if nifedipine and amlodipine, dihydropyridines widely used for high blood pressure and angina, are linked with out-of-hospital cardiac arrest. The nifedipine doses most often used and studied in this investigation are 30 mg and 60 mg (90 mg is available but infrequently used) and the amlodipine doses are 5 mg and 10 mg. Standard practice is to start with a lower dose, then give the higher dose if blood pressure or chest pain are not sufficiently reduced.
The analysis was done using data from the Dutch Amsterdam Resuscitation Studies registry (ARREST, 2005–2011) and confirmed in the Danish Cardiac Arrest Registry (DANCAR, 2001–2014), both part of ESCAPE-NET. Patients with out-of-hospital cardiac arrest due to ventricular fibrillation/tachycardia were enrolled, plus up to five controls per patient matched for age and sex. Controls were from the Dutch PHARMO Database Network and the general population in Denmark. In total, the study included 2,503 patients and 10,543 controls in the ARREST analysis and 8,101 patients and 40,505 controls in the DANCAR analysis.
Current use of high-dose (≥60 mg/day), but not low-dose (<60 mg/day), nifedipine was significantly associated with an increased risk of out-of-hospital cardiac arrest compared to non-use of dihydropyridines, with an odds ratio of 1.5 in ARREST and 2.0 in DANCAR. High-dose nifedipine was also associated with an increased risk of out-of-hospital cardiac arrest when compared with any dose of amlodipine, with odds ratios of 2.3 and 2.2 in the ARREST and DANCAR registries, respectively. There was no risk associated with amlodipine.
The results were supported by a study in human cardiac cells. Dihydropyridines act by blocking L-type calcium channels. The laboratory study showed that at the dosages studied in this investigation, both drugs blocked these ion channels, thereby shortening the action potential of the cardiac cell. A shorter action potential can facilitate the occurrence of the fatal arrhythmias that cause sudden cardiac arrest. High-dose nifedipine (60 mg) caused more shortening of the action potential than high-dose amlodipine (10 mg).
“Nifedipine and amlodipine are often used by many cardiologists and other physicians, and the choice often depends on the prescriber’s preference and personal experience,” said Dr Tan. “Both drugs are generally considered to be equally effective and safe and neither has been associated with sudden cardiac arrest. This study suggests that high-dose nifedipine may increase the risk of sudden cardiac arrest due to fatal cardiac arrhythmia while amlodipine does not. If these findings are confirmed in other studies, they may have to be taken into account when the use of either drug is considered.”
These findings may be surprising given that both drugs have been in use for many years and in many patients. A possible explanation why this discovery has only been made now is that out-of-hospital cardiac arrest is very difficult to study due to its rapid course, and requires dedicated datasets collected specifically for this purpose. Until now, there were insufficient patient records to test the impact of medications. ESCAPE-NET has made this possible by linking large cohorts across Europe, including ARREST and DANCAR.
The work of ESCAPE-NET will be discussed in two sessions at EHRA 2019, highlighting the importance of working across Europe2 and advances in preventing sudden cardiac arrest during sports.3
Dr Tan said: “As a European consortium we can validate our findings in different populations, and we bring together different expertise. For example, sudden cardiac arrest during sports is 19 times more common in men than women and the network enables us to comprehensively evaluate the potential biological (sex) and behavioural (gender) reasons.”
ESCAPE-NET is backed by the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC) and the European Resuscitation Council (ERC).
Authors: ESC Press Office Tel: +33 (0)4 8987 2499 Email: firstname.lastname@example.org
Follow us on Twitter @ESCardioNews
The hashtag for the meeting is #ehra2019.
Sources of funding: Funded by the “Horizon 2020 – the Framework Programme for Research and Innovation (2014-2020)” of the European Union. Grant agreement 73 3381.
References and notes
1The abstract ‘High-dose nifedipine use is associated with increased risk of out-of-hospital cardiac arrest: multi-country case-control study’ will be presented during the Young EP poster session – Young meets Experienced on Sunday March 17 at 08:30 to 18:00 WET (GMT) in the Poster Area.
2The session Sudden cardiac arrest – European perspectives and solutions takes place on Monday 18 March at 14:00 to 15:30 WET (GMT) in the Coumel lecture room.
3The session Sudden cardiac death in sports activities takes place on Monday 18 March at 08:30 to 10:00 WET (GMT) in the Coumel lecture room.
About the European Heart Rhythm Association
The European Heart Rhythm Association (EHRA) is a branch of the European Society of Cardiology (ESC). Its aim is improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances. EHRA ensures the dissemination of knowledge and standard setting; provides continuous education, training and certification to physicians and allied professionals involved in the field of cardiac arrhythmias with a special focus on Atrial Fibrillation (AF) and Electrophysiology (EP). EHRA releases international consensus documents and position papers, it is a source of high quality, unbiased, evidence based, scientific information that promotes the quality of care for patients with AF, and for, has also dedicated a website for patients “afibmatters.org”.
About the EHRA Congress
EHRA 2019 is the annual congress of the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC).
About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.
Information for journalists attending EHRA 2019
EHRA 2019 will be held 17 to 19 March at the Lisbon Congress Centre (CCL) in Lisbon, Portugal. Explore the scientific programme.
Our mission: To reduce the burden of cardiovascular disease.
© 2020 European Society of Cardiology. All rights reserved.